Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Imjudo (tremelimumab-actl) is a CTLA-4 immune checkpoint inhibitor used in combination with durvalumab (Imfinzi) to enhance the immune system's ability to recognize and attack cancer cells.
Imjudo, combined with durvalumab, is FDA-approved for adults with unresectable hepatocellular carcinoma (liver cancer). Combined with durvalumab and platinum-based chemotherapy, it is also approved for adults with metastatic non-small cell lung cancer without sensitizing EGFR mutations or ALK genomic aberrations.
Tremelimumab blocks CTLA-4, a checkpoint protein that normally suppresses T-cell activation, allowing the immune system to mount a stronger anti-tumor response, particularly when combined with the PD-L1 inhibitor durvalumab.
For hepatocellular carcinoma, the standard dose is 300 mg as a single intravenous dose, combined with durvalumab 1500 mg, followed by durvalumab alone every 4 weeks. For NSCLC, tremelimumab is combined with durvalumab and platinum-based chemotherapy per a defined cycle schedule, as determined by the treating oncologist.
Imjudo, as an immune checkpoint inhibitor, can cause immune-mediated adverse reactions affecting multiple organ systems.
Monitor for new or worsening respiratory symptoms; manage with corticosteroids and treatment interruption as needed.
Monitor for diarrhea or signs of colitis.
Monitor liver function tests before and during treatment.
Can affect the thyroid, pituitary, and adrenal glands. Monitor thyroid and other hormone levels periodically.
Monitor kidney function and for skin changes throughout treatment.
Monitor during and after infusion for hypersensitivity reactions.
Imjudo can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Imjudo (tremelimumab-actl) received FDA approval in 2022 and is manufactured by AstraZeneca, used in combination with durvalumab (Imfinzi) for liver cancer and lung cancer.
Import of Imjudo through a Named Patient Program requires a valid prescription from the treating oncologist, diagnostic confirmation and treatment plan documentation, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Imjudo directly from AstraZeneca's authorized supply chain to ensure product authenticity and regulatory compliance.
Imjudo is sourced through verified, GDP-compliant, cold-chain channels from AstraZeneca's authorized supply chain to ensure authenticity and quality.
Imjudo should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Imjudo is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Imjudo through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading oncology centers in Mumbai support liver and lung cancer treatment coordination for Imjudo access.
Delhi's major cancer hospitals assist patients with treatment planning and prescription support for Imjudo.
Bangalore's oncology network offers access to combination immunotherapy planning for eligible patients.
Chennai-based specialists coordinate Imjudo access alongside comprehensive cancer care.
Hyderabad's cancer care institutions support patients pursuing Imjudo therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Imjudo.
Pune-based oncologists assist with treatment planning for Imjudo.
Ahmedabad's specialty hospitals support the import and treatment process for Imjudo.
Kochi's oncology units assist patients with the documentation needed for Imjudo access.
Chandigarh's cancer care centers support Imjudo treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Imjudo access process.
Lucknow-based cancer centers assist patients pursuing Imjudo therapy.
Bhubaneswar's oncology institutions support access to Imjudo for eligible patients.
Guwahati's specialists help coordinate Imjudo access for patients across the Northeast.
Patients in other cities across India can also access Imjudo through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
